
PCI Biotech Investor Relations Material
Latest events

Q4 2024
PCI Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PCI Biotech Holding
Access all reports
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.
Key slides for PCI Biotech Holding


Q4 2024
PCI Biotech Holding


Q4 2024
PCI Biotech Holding
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PCIB
Country
🇳🇴 Norway